What They Have in Common
All three are FDA-approved botulinum toxin type A formulations used for cosmetic wrinkle treatment. All three temporarily relax facial muscles by preventing acetylcholine release at neuromuscular junctions. All three have comparable safety profiles established over decades of use. All three require repeat treatments — they wear off as nerve terminals regenerate.
The shared mechanism is the most important fact. When a provider tells you one product is "significantly better" than another without context, they're usually selling their preferred product, not describing clinical reality.
The Real Differences: Spread, Onset, Duration
| Botox (Allergan) | Dysport (Galderma) | Xeomin (Merz) | |
|---|---|---|---|
| Active ingredient | Botulinum toxin A | Botulinum toxin A | Botulinum toxin A |
| Spread characteristic | More localized | Spreads more widely | Similar to Botox |
| Typical onset | 3–7 days | 2–5 days (slightly faster) | 3–7 days |
| Duration | 3–4 months | 3–4 months | 3–4 months |
| Unit conversion | 1 unit | 2.5–3 units = 1 Botox unit | 1:1 with Botox |
| Complexing proteins | Present | Present | Absent ("naked" toxin) |
| FDA approved (cosmetic) | Yes (2002) | Yes (2009) | Yes (2011) |
The spread difference is the most clinically relevant. Dysport diffuses more widely after injection — roughly 20–30% more spread than Botox at equivalent doses. This can be an advantage in large areas (forehead) where you want even distribution without many injection points, or a disadvantage in precision areas (around the eyes) where you don't want the effect to extend to adjacent muscles.
The onset difference is real but minor. Dysport often shows first effects in 2–3 days vs. Botox's 4–7 days. Whether this matters depends on why you're tracking onset — for most patients, the practical difference is negligible.
Duration is essentially equivalent across all three products for most patients. Individual metabolism affects all three equally.
Xeomin's "naked" formulation — absent the complexing proteins that accompany Botox and Dysport — is the theoretical basis for claims that Xeomin patients are less likely to develop resistance or antibodies. The clinical evidence for this being a meaningful real-world advantage is limited. Most patients never develop meaningful resistance to any product.
Cost Comparison: What You'll Actually Pay in 2026
Botox pricing is discussed per unit because Allergan's brand dominance made per-unit pricing the industry standard. Dysport is typically priced per unit at a lower per-unit rate — but requires more units to achieve equivalent effect. Xeomin is priced at roughly 1:1 with Botox.
| Product | Typical Per-Unit Price | Units for Frown Lines | Effective Treatment Cost |
|---|---|---|---|
| Botox | $10–$22/unit | 20–25 units | $200–$550 |
| Dysport | $4–$7/unit | 50–75 units | $200–$525 |
| Xeomin | $9–$20/unit | 20–25 units | $180–$500 |
Per-session cost is roughly equivalent when unit conversion is properly applied. If a provider is advertising Dysport at a dramatically lower price without adjusting for units — quoting "$4/unit" without noting you'll need 3x the units — that's not a deal, it's math.
Some providers offer Dysport at a genuine slight discount compared to Botox per-session, reflecting their lower acquisition costs. This is where Dysport can provide modest cost savings for repeat patients.
When Dysport Might Be the Better Choice
Dysport's spread characteristic — often viewed as a limitation — is actually an advantage in specific clinical situations.
Large forehead treatment. A wide forehead with significant muscle activity benefits from Dysport's broader diffusion. Fewer injection points can treat a larger area evenly, which some patients and injectors prefer. Less trauma to the skin from injection sites.
Patients who haven't responded well to Botox. A small percentage of patients develop reduced responsiveness to Botox over years of treatment, possibly due to antibody formation against the complexing proteins. Switching to Dysport or Xeomin sometimes restores full effect. This isn't common, but it's a genuine use case.
Patients who track onset carefully. If you're getting Botox before an event and want visible effect in 2–3 days rather than 4–7 days, Dysport's faster onset has practical value.
When Xeomin Has a Case
Xeomin's main theoretical advantage — the absent complexing proteins potentially reducing long-term resistance — is real in theory but largely unproven as a meaningful clinical benefit for most patients. Its practical advantages are:
Long-term maintenance patients. Patients who've had Botox for 10+ years and wonder about resistance may benefit from alternating with Xeomin. The evidence is anecdotal but some injectors swear by rotation protocols.
Price sensitivity. Xeomin is sometimes priced slightly below Botox at practices that pass on lower acquisition costs. Not universal, but worth asking at your clinic.
Patients who've had allergic reactions to Botox. Extremely rare, but the different protein profile of Xeomin means patients with Botox sensitivity may tolerate it better.
For the vast majority of patients getting routine facial Botox — first-timers, maintenance patients, uncomplicated cases — Botox remains the default because of its 20+ year track record and the familiarity most injectors have with it. Dysport and Xeomin are legitimate alternatives, not upgrades or downgrades.
FAQ: Botox vs. Dysport vs. Xeomin
Q: Which lasts longer — Botox, Dysport, or Xeomin?
All three are broadly equivalent in duration: 3–4 months for most patients. Individual metabolism, treatment area, and units used have more impact on duration than product choice.
Q: Is Dysport cheaper than Botox?
Per unit, yes — Dysport costs $4–$7/unit vs. Botox's $10–$22/unit. But Dysport requires approximately 2.5–3 units per 1 Botox unit of effect. The per-session cost for an equivalent treatment is roughly the same. Some practices price Dysport at a slight session-level discount; others charge the same.
Q: Can I switch between products?
Yes. Your injector will convert units appropriately. Some patients deliberately rotate between products; others switch when pricing or availability changes. There's no medical reason to stay committed to one product indefinitely.
Q: Does Dysport spread to areas you don't want it to?
This concern is legitimate — Dysport's wider diffusion is a real characteristic. In the hands of an experienced injector who accounts for this during dosing and placement, it's managed easily. In the hands of an inexperienced injector, it can produce effects in unintended areas. This is an argument for provider experience, not against Dysport specifically.
Q: Which do most med spas use?
Botox is by far the most commonly used in US med spas — it has the largest brand awareness, the longest approval history, and the clearest patient expectations. Dysport is widely available as a second option. Xeomin is available at a smaller number of practices. All three are equally legitimate options.
Q: Is Xeomin better for people who've "built up a tolerance" to Botox?
Tolerance development is rare and the evidence that the naked toxin of Xeomin prevents it is limited. If you feel Botox results are diminishing, the more likely explanations are: insufficient unit dosing (different providers use different doses), anatomical changes over time, or technique differences between providers. Switching products is worth discussing with your injector, but it's not a guaranteed fix.
Find a Verified Med Spa Near You
Looking for neurotoxin treatments? Browse verified providers at med spas in Los Angeles, med spas in Miami, and med spas in Dallas. For the full Botox treatment guide, visit the Botox page.